Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

54.09
-0.6900-1.26%
Post-market: 54.090.00000.00%16:10 EDT
Volume:1.70M
Turnover:91.56M
Market Cap:10.39B
PE:30.05
High:54.37
Open:54.36
Low:53.36
Close:54.78
52wk High:73.18
52wk Low:50.76
Shares:192.11M
Float Shares:178.10M
Volume Ratio:0.62
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.80
EPS(LYR):1.80
ROE:5.94%
ROA:5.58%
PB:1.71
PE(LYR):30.05

Loading ...

BRIEF-U.S. Food And Drug Administration Approves Biomarin's Palynziq® (Pegvaliase-Pqpz) For Adolescents 12 Years Of Age And Older With Phenylketonuria (Pku)

Reuters
·
Feb 28

FDA approves BioMarin PALYNZIQ for adolescents 12 and older with PKU

Reuters
·
Feb 28

Ascendis wins U.S. approval for therapy for children with dwarfism

Reuters
·
Feb 28

BioMarin EVP and Chief Legal Officer George Eric Davis Disposes of Common Shares

Reuters
·
Feb 27

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Feb 27

These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results

Benzinga_recent_news
·
Feb 26

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Feb 25

BioMarin price target lowered to $86 from $106 at Guggenheim

TIPRANKS
·
Feb 25

Barclays Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Stock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences

Stock Track
·
Feb 24

Stock Track | Biomarin Pharmaceutical Plummets 5.15% in Pre-Market After Oppenheimer Cuts Price Target

Stock Track
·
Feb 24

Stock Track | Biomarin Pharmaceutical Plunges 5.09% in Pre-Market After Oppenheimer Cuts Target Price

Stock Track
·
Feb 24

BioMarin to Attend Four Investor Conferences in March

Reuters
·
Feb 24

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Feb 24

Cantor Fitzgerald Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Feb 24

Biomarin Pharmaceutical Q4 Adj. EPS $0.46 Misses $0.63 Estimate, Sales $875.000M Beat $827.969M Estimate

Benzinga
·
Feb 24

BioMarin Q4 net income swings to a GAAP net loss of USD 47 million on 17% revenue growth to USD 875 million

Reuters
·
Feb 24

BRIEF-Biomarin Pharmaceutical Q4 EPS USD -0.24

Reuters
·
Feb 24

Biomarin Pharmaceutical Q4 Adjusted EPS USD 0.46 VS. Ibes Estimate USD 0.62

THOMSON REUTERS
·
Feb 24